A Call for Greater Consideration for the Role of Vaccines in National Strategies to Combat Antibiotic-Resistant Bacteria: Recommendations from the National Vaccine Advisory Committee

Review on Antimicrobial Resistance. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. 2014 [cited 2015 Mar 14]. Available from: http://www.jpiamr.eu/wp-content/uploads/2014/12/AMR-review-paper-tackling-a-crisis-for-the-health-and-wealth-of-nations_1–2.pdf.

Centers for Disease Control and Prevention (US). Antibiotic resistance threats in the United States, 2013. 2014 [cited 2015 Mar 14]. Available from: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.

Keown OP Warburton W Davies SC Darzi A. Antimicrobial resistance: Addressing the global threat through greater awareness and transformative action. Health Aff 2014;33:1620–6.

The White House (US). National strategy for combating antibiotic-resistant bacteria. 2014 [cited 2015 Mar 16]. Available from: https://www.whitehouse.gov/sites/default/files/docs/carb_national_strategy.pdf.

President's Council of Advisors on Science and Technology. Report to the president on combating antibiotic resistance. 2014 [cited 2015 Mar 16]. Available from: https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf.

The White House (US). Executive order—combating antibiotic-resistant bacteria. 2014 [cited 2015 Mar 16]. Available from: https://www.whitehouse.gov/the-press-office/2014/09/18/executive-order-combating-antibiotic-resistant-bacteria.

The White House (US). National action plan for combating antibiotic-resistant bacteria. 2015 [cited 2015 Mar 27]. Available from: https://www.whitehouse.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf.

The White House (US), Office of the Press Secretary. Fact sheet: President's 2016 budget proposes historic investment to combat antibiotic-resistant bacteria to protect public health. 2015 Jan 27 [cited 2015 Mar 16]. Available from: https://www.whitehouse.gov/the-press-office/2015/01/27/fact-sheet-president-s-2016-budget-proposes-historic-investment-combat-a.

Roush SW, Murphy TV; Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007;298:2155–63.

Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1993;42(RR-13): 1–15.

Mason EO Kaplan SL Lamberth LB Hinds DB Kvernland SJ Loiselle EM , Serotype and ampicillin susceptibility of Haemophilus influenzae causing systemic infections in children: 3 years of experience. J Clin Microbiol 1982;15:543–6.

Adams DA Jajosky RA Ajani U Kriseman J Sharp P Onwen DH , Summary of notifiable diseases—United States, 2012. MMWR Morb Mortal Wkly Rep 2014;61(53):1–121.

Department of Health and Human Services (US). Healthy People 2020—immunization and infectious diseases. 2015 [cited 2015 Mar 23]. Available from: https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives.

Barbour ML . Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg Infect Dis 1996;2:176–82.

Whitney CG Farley MM Hadler J Harrison LH Lexau C Reingold A , Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917–24.

Kyaw MH Lynfield R Schaffner W Craig AS Hadler J Reingold A , Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455–63.

Wilby KJ Werry D. A review of the effect of immunization programs on antimicrobial utilization. Vaccine 2012;30:6509–14.

Cohen R. The need for prudent use of antibiotics and routine use of vaccines. Clin Microbiol Infect 2009;15(Suppl 3):21–3.

Lee GC Reveles KR Attridge RT Lawson KA Mansi IA Lewis JS 2nd Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med 2014;12:96.

Fireman B Black SB Shinefield HR Lee J Lewis E Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis 2003;22:10–6.

Hicks LA Harrison LH Flannery B Hadler JL Schaffner W Craig AS , Incidence of pneumococcal disease due to nonpneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis 2007;196:1346–54.

Moore MR Link-Gelles R Schaffner W Lynfield R Lexau C Bennett NM , Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: Analysis of multisite, population-based surveillance. Lancet Infect Dis 2015;15:301–9.

Tomczyk S Bennett NM Stoecker C Gierke R Moore MR Whitney CG , Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63(37):822–5.

Grijalva C Wunderink R Williams D Al E. Distribution of pneumococccal serotypes detected through urine analysis among US adults hospitalized with pneumonia after introduction of PCV13. In: International Symposium on Pneumococci and Pneumococcal Diseases 2014; 2014 Mar 9–13; Hyderabad, India.

Misurski DA Lipson DA Changolkar AK . Inappropriate antibiotic prescribing in managed care subjects with influenza. Am J Manag Care 2011;17:601–8.

Kash JC Taubenberger JK . Infectious disease theme issue: The role of viral, host, and secondary bacterial factors in influenza pathogenesis. Am J Pathol 2015;185:1528–36.

Centers for Disease Control and Prevention. Flu vaccination coverage, United States, 2013–14 influenza season. 2014 [cited 2015 Mar 27]. Available from: http://www.cdc.gov/flu/fluvaxview/coverage-1314estimates.htm.

Kwong JC Maaten S Upshur REG Patrick DM Marra F. The effect of universal influenza immunization on antibiotic prescriptions: An ecological study. Clin Infect Dis 2009;49:750–6.

Kallen AJ Mu Y Bulens S Reingold A Petit S Gershman K , Health care-associated invasive MRSA infections, 2005–2008. JAMA 2010;304:641–8.

Dantes R Mu Y Belflower R Aragon D Dumyati G Harrison LH , National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013;173:1970–8.

Centers for Disease Control and Prevention (US). Active Bacterial Core surveillance report, Emerging Infections Program Network, methicillin-resistant Staphylococcus aureus, 2012. 2012 [cited 2015 Mar 29]. Available from: http://www.cdc.gov/abcs/reports-findings/survreports/mrsa12.pdf.

Daum RS Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 2012;54:560–7.

Kaslow DC Shiver JW . Clostridium difficile and methicillin-resistant Staphylococcus aureus: Emerging concepts in vaccine development. Annu Rev Med 2011;62:201–15.

Lessa FC Gould C V McDonald LC . Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012;55(Suppl 2):S65–70.

Rupnik M Wilcox MH Gerding DN . Clostridium difficile infection: New developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009;7:526–36.

Chitnis AS Holzbauer SM Belflower RM Winston LG Bamberg WM Lyons C , Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013;173:1359–67.

Lessa FC Mu Y Bamberg WM Beldavs ZG Dumyati GK Dunn JR , Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825–34.

Lo Vecchio A Zacur GM . Clostridium difficile infection: An update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012;28:1–9.

Gerding DN Johnson S. Management of Clostridium difficile infection: Thinking inside and outside the box. Clin Infect Dis 2010;51:1306–13.

Lee BY Popovich MJ Tian Y Bailey RR Ufberg PJ Wiringa AE , The potential value of Clostridium difficile vaccine: An economic computer simulation model. Vaccine 2010;28(:5245–53.

McGlone SM Bailey RR Zimmer SM Popovich MJ Tian Y Ufberg P , The economic burden of Clostridium difficile. Clin Microbiol Infect 2012;18:282–9.

O'Brien JA Lahue BJ Caro JJ Davidson DM . The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: Clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28:1219–27.

Department of Health and Human Services (US), Office of the Assistant Secretary for Planning and Evaluation. Analytical framework for examining the value of antibacterial products. 2014 [cited 2015 May 30]. Available from: http://aspe.hhs.gov/sp/reports/2014/antibacterials/rpt_antibacterials.cfm.

Sahoo A. Vaccines 2011: Market analysis, key players and critical trends in a fast-changing industry. Rockville (MD): Kalorama Information; 2011.